138 related articles for article (PubMed ID: 19883155)
21. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
22. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
Behra-Miellet J; Dubreuil L; Calvet L
Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
[TBL] [Abstract][Full Text] [Related]
25. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
Nilsson LE; Frimodt-Møller N; Vaara M; Simonsen GS;
Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008.
Wang YF; Dowzicky MJ
Diagn Microbiol Infect Dis; 2010 Sep; 68(1):73-9. PubMed ID: 20727474
[TBL] [Abstract][Full Text] [Related]
27. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections.
Petersen PJ; Ruzin A; Tuckman M; Jones CH
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):407-18. PubMed ID: 20226331
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
Somily AM; Al-Khattaf AS; Kambal AM
Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893
[TBL] [Abstract][Full Text] [Related]
31. Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens.
Arya SC; Agarwal N
Saudi Med J; 2008 Nov; 29(11):1558-60. PubMed ID: 18998000
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
Fritsche TR; Jones RN
Int J Antimicrob Agents; 2004 Dec; 24(6):567-71. PubMed ID: 15555879
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
Reinert RR; Low DE; Rossi F; Zhang X; Wattal C; Dowzicky MJ
J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
[TBL] [Abstract][Full Text] [Related]
34. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
36. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007.
Jamal W; Shahin M; Rotimi VO
Anaerobe; 2010 Feb; 16(1):1-5. PubMed ID: 19406247
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.
Souli M; Kontopidou FV; Koratzanis E; Antoniadou A; Giannitsioti E; Evangelopoulou P; Kannavaki S; Giamarellou H
Antimicrob Agents Chemother; 2006 Sep; 50(9):3166-9. PubMed ID: 16940120
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Bradford PA; Weaver-Sands DT; Petersen PJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of tigecycline against Bacteroides species.
Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
[TBL] [Abstract][Full Text] [Related]
40. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
Tsao SM; Lin HC; Lee CM; Hsu GJ; Chen CM; Sun W; Liu YC; Jang TN; Cheng YJ; Lu PL; Chiang PC; Wang LS; Kung HC; Chuang YC; Shi ZY; Liu JW; Huang CH; Lu CT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S184-7. PubMed ID: 19013352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
